| The Efficacy and Safety of Switch Between Agalsidase Beta to Agalsidase Alfa for Enzyme Replacement in Patients With Anderson-Fabry Disease (NCT01268241) | CENTOGENE GmbH Rostock | 2010-12-01 |
| Androgenetic Alopecia in Fabry Disease (NCT01295008) | Baylor Research Institute | 2010-12-01 |
| Sophisticated Assessment of Disease Burden in Patients With Fabry Disease (NCT01210196) | Shire | 2010-10-31 |
| Natural History and Structural Functional Relationships in Fabry Renal Disease Treatment Outcomes(Changes)in Fabry Renal Disease Study (NCT01581424) | University of Minnesota | 2010-10-01 |
| Establishment of Biomarkers for Fabry Disease (NCT01165697) | Ohio State University | 2010-07-01 |
| Extension Study of TKT028 Evaluating Safety and Clinical Outcomes of Replagal® in Adult Patients With Fabry Disease (NCT01124643) | Shire | 2010-04-13 |
| Precision Diagnosis and Risk Stratification of Rare Cardiomyopathies Based on Novel Cardiac Magnetic Resonance Techniques (NCT07336394) | Chinese Academy of Medical Sciences, Fuwai Hospital | 2010-01-01 |
| National Registry of Rare Kidney Diseases (NCT06065852) | UK Kidney Association | 2009-11-06 |
| Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease (NCT00925301) | Amicus Therapeutics | 2009-10-23 |
| Study of the Spermatic Characteristics of Patients With Fabry Disease (NCT04073888) | University Hospital, Bordeaux | 2009-02-20 |
| Fabry Screening Study (NCT01019629) | Baylor Research Institute | 2009-01-29 |
| Viennese Prevalence Study of Anderson-Fabry Disease (NCT00871611) | Medical University of Vienna | 2009-01-01 |
| Safety and Efficacy Study of Several Replagal Dosing Regimens on Cardiac Function in Adults With Fabry Disease (NCT00864851) | Shire | 2008-12-29 |
| A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms (NCT00701415) | Genzyme, a Sanofi Company | 2008-09-01 |
| Open-label Long-term Safety Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Who Have Completed a Previous AT1001 Study (NCT00526071) | Amicus Therapeutics | 2007-09-17 |
| Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation (NCT00413595) | CENTOGENE GmbH Rostock | 2007-07-01 |
| The Fabrazyme® and Arbs and ACE Inhibitor Treatment (FAACET) Study (NCT00446862) | University of Alabama at Birmingham | 2007-03-01 |
| Canadian Fabry Disease Initiative (CFDI) National Registry (NCT00455104) | Canadian Fabry Research Consortium | 2007-01-01 |
| A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Female Participants With Fabry Disease (NCT00304512) | Amicus Therapeutics | 2006-09-07 |
| A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease (NCT00283959) | Amicus Therapeutics | 2006-06-27 |
| Study of the Effects of Fabrazyme Treatment on Lactation and Infants (NCT00230607) | Genzyme, a Sanofi Company | 2006-05-28 |
| A 24-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease (NCT00283933) | Amicus Therapeutics | 2006-05-09 |
| A Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease (NCT00214500) | Amicus Therapeutics | 2006-01-02 |
| A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry Disease (NCT00140621) | Genzyme, a Sanofi Company | 2005-07-01 |
| Evaluation of Efficacy and Safety of Agalsidase Beta in Heterozygous Females for Fabry Disease (NCT00487630) | Assistance Publique - Hôpitaux de Paris | 2005-06-01 |
| Study to Collect Data on Fabry Disease Patients With Enhanceable Alpha-Galactosidase A Activity (NCT00106912) | National Institute of Neurological Disorders and Stroke (NINDS) | 2005-03-28 |
| Replagal Enzyme Replacement Therapy for Adults With Fabry Disease (NCT00097890) | National Institute of Neurological Disorders and Stroke (NINDS) | 2004-11-01 |
| Replagal Enzyme Replacement Therapy for Children With Fabry Disease (NCT00084084) | Shire | 2004-06-10 |
| A Long Term Safety and Efficacy Study of Fabrazyme Replacement Therapy in Japanese Patients With Fabry Disease. (NCT00233870) | Genzyme, a Sanofi Company | 2004-06-01 |
| A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease (NCT00081497) | Genzyme, a Sanofi Company | 2004-01-01 |
| Alternative Dosing and Regimen of Replagal to Treat Fabry Disease (NCT00075244) | National Institute of Neurological Disorders and Stroke (NINDS) | 2004-01-01 |
| Neuropathic Pain and Fabry Disease (NCT00168974) | Danish Pain Research Center | 2004-01-01 |
| An Open-Label Clinical Trial of Replagal Enzyme Therapy in Children Ages 7-17 Years With Fabry Disease (NCT00071877) | National Institute of Neurological Disorders and Stroke (NINDS) | 2003-10-01 |
| An Open-Label Maintenance Study of the Enzyme Replacement Therapy Replagal in Patients With Fabry Disease (NCT00357786) | National Institute of Neurological Disorders and Stroke (NINDS) | 2003-10-01 |
| Dosing Study of Replagal in Patients With Fabry Disease (NCT00068107) | Baylor Research Institute | 2003-09-01 |
| A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease (NCT00196716) | Genzyme, a Sanofi Company | 2003-06-01 |
| Registry of Fabry Disease - A Multicenter Observational Study (NCT00055016) | National Institute of Neurological Disorders and Stroke (NINDS) | 2003-02-13 |
| Severe Renal Disease Study in Fabry Patients Treated With Fabrazyme (NCT00837824) | Genzyme, a Sanofi Company | 2002-12-01 |
| Enzyme Replacement Therapy in Fabry Disease (NCT00149318) | Mario Negri Institute for Pharmacological Research | 2002-12-01 |
| A Study of Fabrazyme in Pediatric Patients With Fabry Disease (NCT00074958) | Genzyme, a Sanofi Company | 2002-10-01 |
| Data Collection in Women With Fabry Disease (NCT00030134) | National Institute of Neurological Disorders and Stroke (NINDS) | 2002-01-01 |
| Ophthalmic Findings During 10-year Enzyme Substitution of Danish Fabry Patients. (NCT01997489) | Rigshospitalet, Denmark | 2001-09-01 |
| Fabry Disease Registry & Pregnancy Sub-registry (NCT00196742) | Genzyme, a Sanofi Company | 2001-07-31 |
| A Study of the Safety and Efficacy of Fabrazyme (Agalsidase Beta) as Compared to Placebo in Patients With Advanced Fabry Disease (NCT00074984) | Genzyme, a Sanofi Company | 2001-02-01 |
| Antiproteinuric Agents and Fabry Disease (NCT00343577) | University of Alabama at Birmingham | 2001-01-01 |
| Evaluation of HEArt invoLvement in Patients With FABRY Disease (NCT03362164) | Wuerzburg University Hospital | 2001-01-01 |
| PET Scans in Normal Volunteers and Patients With Fabry Disease (NCT00005111) | National Institute of Neurological Disorders and Stroke (NINDS) | 2000-04-01 |
| A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease (NCT00074971) | Genzyme, a Sanofi Company | 1999-10-01 |
| Vasodilation in Patients With Fabry's Disease (NCT00001774) | National Institute of Neurological Disorders and Stroke (NINDS) | 1997-10-01 |
| Physician Initiated Expanded Access Request for Migalastat in Individual Patients With Fabry Disease (NCT01476163) | Amicus Therapeutics | |
| Post Trial Access to Lucerastat for Patients With Fabry Disease Who Participated in Study ID-069A302 (NCT07762638) | Idorsia Pharmaceuticals Ltd. | |
| Open-Label Expanded Access Treatment With Pegunigalsidase Alfa for Fabry Disease Patients (NCT04552691) | Chiesi Farmaceutici S.p.A. | |
| Treatment Protocol of Replagal for Patients With Fabry Disease (NCT01031173) | Shire | |